Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study-Reference-Cited by-同舟云学术

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Published:2021-02-05 Issue:2 Volume:16 Page:165-176
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Cheng Ying^ORCID,He Yong,Li Wei,Zhang He-long,Zhou Qing,Wang Buhai,Liu Chunling,Walding Andrew,Saggese Matilde,Huang Xiangning,Fan Minhao,Wang Jia,Ramalingam Suresh S.

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-021-00794-6.pdf

Reference27 articles.

1. Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, et al. Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer. Oncologist. 2019;24(11):e1070–81. https://doi.org/10.1634/theoncologist.2018-0572.

2. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–93. https://doi.org/10.18632/oncotarget.12587.

3. Liang H, Song X, Zhang Y, Zhang S, Li F, Fang J, et al. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: a prospective observational study. Thorac Cancer. 2019;10(7):1521–32. https://doi.org/10.1111/1759-7714.13090.

4. Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer. 2014;110(11):2812–20. https://doi.org/10.1038/bjc.2014.210.

5. Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS. SSO and TOS Ann Oncol. 2019;30(2):171–210. https://doi.org/10.1093/annonc/mdy554.

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-09-11

2. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23

3. Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis;BMJ Supportive & Palliative Care;2024-08-19

4. Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs;Future Oncology;2024-08-19

5. Comprehensive Potential of Artificial Intelligence for Predicting PD-L1 Expression and EGFR Mutations in Lung Cancer: A Systematic Review and Meta-Analysis;Journal of Computer Assisted Tomography;2024-08-12